（文章来源：每日经济新闻） 华福证券指出，TPD赛道研发火热，蛋白降解技术（包括分子胶、PROTAC等）在自身免疫疾病领域进 展迅速，STAT6、IRAK4、IRF5、VAV1、NLRP3、NEK7等热门小分子靶点备受关注。这些靶点在临床 或临床前阶段展现出优异疗效与安全性，为自免疾病治疗开辟新路径。从2026年开始，众多自免TPD靶 点将迎来数据读出，或进入到临床关键性阶段，值得重点关注。在医疗器械领域，设备方面关注补库和 招投标，如手术机器人和内镜等；耗材方面关注集采受益的创新耗材，如神经介入、外周介入和电生理 等方向。 科创创新药ETF国泰（589720）跟踪的是科创新药指数（950161），单日涨跌幅限制达20%，该指数聚 焦于科技创新驱动的新型药物研发领域，成分股涵盖从事创新药物研究、开发与生产的上市公司。指数 侧重于生物医药行业的高成长性和创新性，以反映相关企业在新药研发方面的表现及市场价值。 ...

华福证券指出，TPD赛道研发火热，蛋白降解技术在自身免疫疾病领域进展迅速，STAT6、IRAK4、 IRF5、VAV1、NLRP3、NEK7等热门小分子靶点备受关注。目前这些靶点在临床或临床前阶段展现出 优异疗效与安全性，为自免疾病治疗开辟新路径。2026年开始，众多自免TPD靶点将迎来数据读出，或 进入到临床关键性阶段。对于医疗器械行业，设备方面关注补库和招投标，如手术机器人和内镜等；耗 材方面关注集采受益的创新耗材，如神经介入、外周介入和电生理等方向。 创业板医药ETF国泰（159377）跟踪的是创医药指数（399275），单日涨跌幅限制达20%，该指数从沪 深市场中选取从事生物制药、化学制药、中药及医疗服务等创新医药健康领域的上市公司证券作为指数 样本，以反映创新生物医药相关上市公司证券的整体表现。指数注重成分企业的研发投入与技术领先 性，聚焦于具有高成长潜力的医药健康板块。 （文章来源：每日经济新闻） 风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供参 考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构成 投资建议或承诺。提及 ...

Summary of Conference Call for Yuan Dong Bio (苑东生物) Company Overview - **Company**: Yuan Dong Bio (苑东生物) - **Industry**: Pharmaceutical, focusing on drug development and research Key Points R&D Performance and Future Outlook - Yuan Dong invests 20% of its revenue annually in R&D, ranking among the top in the A-share market [3] - The company is transitioning from high-end generic drugs to more competitive controlled narcotics, achieving significant results [3] - Two Class II controlled narcotics, Nabuphine and Butorphanol, are expected to be approved in 2024, with sales projected to grow from 60 million RMB in 2025 to over 200 million RMB by 2026 [3][4] - The company faces challenges in the non-controlled antagonist product segment due to centralized procurement impacts, and its efficiency in developing new Class I drugs is lagging behind competitors [3][5] Strategic Developments - The Shanghai Chaoyang platform enhances the company's capabilities in developing Class I new drugs, particularly the IKZF13 molecular glue for multiple myeloma, which has a significant market potential [6][7] - HP001, a new drug in clinical trials, shows promising results with an objective response rate (ORR) of 83.3% in high-dose groups, outperforming some combination therapies [10] Competitive Landscape - The company is monitoring competition from BeiGene and Nurix in the BTK ProTech product space, with HP002 aiming to replicate BeiGene's success [11] - VAVONE molecular glue HP003 is being developed to target autoimmune oral therapies, showing better efficacy than existing products [12] Future R&D Directions - The company plans to extend its R&D focus to the Dac platform, utilizing molecular glue as a payload, with promising preliminary data [13] - Key developments expected by 2026 include significant data from VIV1 molecular glue, BDK protect IND, and IKZF13 molecules [13] Financial Projections - The overall valuation of the company is projected to reach 25.5 billion RMB by 2026, with the main business valued at approximately 8 billion RMB [14] - Anticipated profits for 2025 are estimated between 270 million to 280 million RMB, with a growth rate of over 20% expected to continue [14][15] Additional Insights - The company has faced challenges in the past few years, particularly in the Class I new drug sector, with only one drug entering Phase I clinical trials in the last decade [5] - The focus on improving R&D efficiency and quality is expected to positively influence future operational trends [15]

Company Overview - Lingke Pharmaceutical has submitted its IPO application to the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] - Founded in November 2017 in Hangzhou by former executives from Pfizer, Merck, and Johnson & Johnson, the company focuses on the development of small molecule targeted innovative drugs for diseases such as cancer, immunity, and inflammation [1][2] - The company’s core products are in the clinical key stage, but financial data indicates significant pressure [1] Product Pipeline - The core competitiveness of Lingke Pharmaceutical lies in two main areas: JAK-STAT signaling pathway drugs and protein degradation technology [2] - The lead product, LNK01001, is a highly selective second-generation JAK1 inhibitor, currently undergoing three Phase III clinical trials for atopic dermatitis, rheumatoid arthritis, and ankylosing spondylitis, with new drug applications planned for 2026 and 2027 [2][3] - Another key product, LNK01004, is a potential first-in-class third-generation pan-JAK inhibitor, which has shown promising results in Phase II trials for atopic dermatitis [2][3] Research and Development - Lingke Pharmaceutical plans to initiate Phase II clinical trials for chronic hand eczema and vitiligo in China in 2026, and advance Phase III trials for atopic dermatitis in 2027 [3] - The company’s IsoNova protein degradation platform significantly enhances target selectivity and reduces off-target risks, shortening the R&D cycle from 18-24 months to just a few months for some candidates [3] - The R&D team consists of 57 members, with a strong focus on new drug exploration and clinical development, holding 53 issued patents and 106 pending patent applications [3] Financial Performance - Lingke Pharmaceutical has reported net losses of 260 million yuan and 312 million yuan for 2023 and 2024, respectively, with a loss of 145 million yuan in the first three quarters of 2025 [4] - The company’s cash flow from operating activities was negative, with net cash flows of -228 million yuan and -241 million yuan for 2023 and 2024, improving to -85.67 million yuan in 2025 [4][5] - The company primarily relies on equity financing for operations and has established a commercial partnership with Xiansheng Pharmaceutical for the commercialization of LNK01001 [5] Market Landscape - The global JAK inhibitor market is highly competitive, projected to grow from 13.9 billion USD in 2024 to 40.8 billion USD by 2033, with the Chinese market expected to increase from 3.8 billion yuan in 2024 to 46.5 billion yuan by 2033 [6] - Major multinational pharmaceutical companies like Pfizer and AbbVie have established a competitive advantage, while several domestic companies are also in Phase III clinical trials for their JAK inhibitors [6]

Core Viewpoint - Haichuang Pharmaceutical (688302) is focusing on the sales strategy of its drug, Dihenzalutamide, which is expected to fill a clinical gap in treating specific mCRPC patients and has significant market potential in China [1][2]. Group 1: Sales Strategy and Market Position - The sales strategy for Dihenzalutamide revolves around a "medical-market-access-sales" four-wheel drive model, emphasizing the establishment of new standards and accumulation of real-world data [1]. - The drug has a differentiated competitive advantage compared to competitors, significantly improving the primary endpoint by extending rPFS by 5.5 months and reducing the risk of imaging progression or death by 42% [1][2]. - The prostate cancer market in China is projected to reach 50 billion by 2030, indicating substantial market potential for Dihenzalutamide [1]. Group 2: Clinical Research and Development - Dihenzalutamide has been included in the CSCO guidelines in 2023 and is expected to be included again after product approval in 2025 [2]. - The company has been exploring protein degradation technology since 2016 and has developed a mature PROTC and molecular glue technology platform [2]. - HP518 is the first oral R PROTC drug in clinical trials in China, with the first subject enrolled in a Phase II trial expected to complete by December 2024 [2]. Group 3: Financial and Operational Outlook - The company plans to maintain annual R&D expenditures at around 200 million over the next 2-3 years, with cash reserves of 880 million as of March 2025 [2]. - The company is considering refinancing needs based on product commercialization and progress of ongoing projects [2]. - An experienced business development team has been established overseas to advance various business development activities [2].